[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642548":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":184,"collaborators":11,"id":186,"slug":187,"hasResults":188,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":11,"eligibilityCriteria":192,"healthyVolunteers":188,"sex":193,"minAge":194,"maxAge":11,"enrollmentInfo":195,"targetDuration":11,"studyType":198,"phases":199,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":214,"whyStopped":11,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},{"fullName":5,"class":6},"Jacobio Pharmaceuticals Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose escalation\u002Fbackfill","EXPERIMENTAL",null,[13],"Drug: JAB-23E73 tablet，nab-paclitaxel，gemcitabine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","JAB-23E73 tablet，nab-paclitaxel，gemcitabine","Orally, intravenous (IV) infusion",[9],[21],{"name":22,"affiliation":22,"role":23},"Jacobio Pharmaceuticals","STUDY_DIRECTOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":11,"email":28},"CONTACT","86 10 56315466","clinicaltrials@jacobiopharma.com",[30,47,61,70,82,94,106,120,132,144,153,163,175],{"facility":31,"status":11,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Beijing Cancer Hospital","Beijing","Beijing Municipality","100142","China","CN",{"type":38,"coordinates":39},"Point",[40,41],116.39723,39.9075,{"lat":41,"lon":40},[44],{"name":31,"role":26,"phone":45,"phoneExt":11,"email":46},"86+13911219511","doctorshenlin@sina.com",{"facility":48,"status":11,"city":49,"state":50,"zip":51,"country":35,"countryCode":36,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Zhejiang Cancer Hospital","Hangzhou","Zhejiang","310005",{"type":38,"coordinates":53},[54,55],120.16142,30.29365,{"lat":55,"lon":54},[58],{"name":48,"role":26,"phone":59,"phoneExt":11,"email":60},"86+13858195803","hzyingjieer@163.com",{"facility":62,"status":11,"city":32,"state":11,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},"Beijing Tsinghua Changgung Hospital",{"type":38,"coordinates":64},[40,41],{"lat":41,"lon":40},[67],{"name":62,"role":26,"phone":68,"phoneExt":11,"email":69},"86+13366152815","joelbmu@126.com",{"facility":71,"status":11,"city":72,"state":11,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Hunan Cancer Hospital","Changsha",{"type":38,"coordinates":74},[75,76],112.97087,28.19874,{"lat":76,"lon":75},[79],{"name":71,"role":26,"phone":80,"phoneExt":11,"email":81},"86+18673181133","liuzhenyang@hnca.org.cn",{"facility":83,"status":11,"city":84,"state":11,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Harbin Medical University Cancer Hospital","Harbin",{"type":38,"coordinates":86},[87,88],126.65,45.75,{"lat":88,"lon":87},[91],{"name":83,"role":26,"phone":92,"phoneExt":11,"email":93},"86+13845120210","yanqiaozhang@126.com",{"facility":95,"status":11,"city":96,"state":11,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Jiangsu Province Hospital","Nanjing",{"type":38,"coordinates":98},[99,100],118.77778,32.06167,{"lat":100,"lon":99},[103],{"name":95,"role":26,"phone":104,"phoneExt":11,"email":105},"86+13585172066","Xiaofengch198019@126.com",{"facility":107,"status":11,"city":108,"state":11,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Shanghai Jiaotong University School of Medicine Ruijin Hospital","Shanghai",{"type":38,"coordinates":110},[111,112],121.45806,31.22222,{"lat":112,"lon":111},[115],{"name":116,"role":26,"phone":117,"phoneExt":118,"email":119},"Shanghai Jiaotong University School of Medicine Ruijin Hospita","86+","86+13901943778","shenby@shsmu.edu.cn",{"facility":121,"status":11,"city":122,"state":11,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"ShanXi Cancer Hospital","Taiyuan",{"type":38,"coordinates":124},[125,126],112.56028,37.86944,{"lat":126,"lon":125},[129],{"name":121,"role":26,"phone":130,"phoneExt":11,"email":131},"86+13811176181","WXCAMS@126.com",{"facility":133,"status":11,"city":134,"state":11,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Hubei Province Hospital","Wuhan",{"type":38,"coordinates":136},[137,138],114.26667,30.58333,{"lat":138,"lon":137},[141],{"name":133,"role":26,"phone":142,"phoneExt":11,"email":143},"86+15629019627","971070316@qq.com",{"facility":145,"status":11,"city":134,"state":11,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":146,"geoPoint":148,"contacts":149},"Wuhan Union Hospital Of China",{"type":38,"coordinates":147},[137,138],{"lat":138,"lon":137},[150],{"name":145,"role":26,"phone":151,"phoneExt":11,"email":152},"86+13720117761","heshuiwu@hust.ed.cn",{"facility":154,"status":11,"city":134,"state":11,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":155,"geoPoint":157,"contacts":158},"Zhongnan Hospital of Wuhan University",{"type":38,"coordinates":156},[137,138],{"lat":138,"lon":137},[159],{"name":154,"role":26,"phone":160,"phoneExt":161,"email":162},"86+13971235235","86-13971235235","pjxp888@126.com",{"facility":164,"status":11,"city":165,"state":11,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"Henan Cancer Hospital","Zhengzhou",{"type":38,"coordinates":167},[168,169],113.64861,34.75778,{"lat":169,"lon":168},[172],{"name":164,"role":26,"phone":173,"phoneExt":11,"email":174},"86+13937100233","2290773710@qq.com",{"facility":176,"status":11,"city":165,"state":11,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":177,"geoPoint":179,"contacts":180},"The First Affiliated hospital of Zhengzhou University",{"type":38,"coordinates":178},[168,169],{"lat":169,"lon":168},[181],{"name":176,"role":26,"phone":182,"phoneExt":11,"email":183},"86+13676932999","yanruqin@163.com",{"type":185,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100642548","phase-1-study-of-jab-23e73-in-combination-with-chemotherapy-in-participants-with-metastatic-pdac-harboring-kras-gene-alterations-100642548",false,"NCT07640295","Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations","A Multicenter, Phase Ib\u002FIII Study to Evaluate JAB-23E73 in Combination With Nab-Paclitaxel and Gemcitabine in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Harboring KRAS Gene Alterations","Inclusion Criteria:\n\n1.Written informed consent signed by the participant or the participant's legally authorized representative must be obtained prior to performing any study-related procedures. 2. Histologically or cytologically confirmed metastatic PDAC.\n\n3\\. No prior systemic antitumor therapy for advanced disease (treatment-naïve). 4. Presence of KRAS gene alterations: be enrolled upon approval by the sponsor).\n\n5\\. ECOG performance status score of 0 or 1. 6. Adequate organ function.\n\nExclusion Criteria:\n\n1. Inability to swallow oral medications or the presence of gastrointestinal dysfunction or disease that may significantly alter drug absorption.\n2. A history of another malignancy within 2 years prior to the first dose, histologically distinct from the cancer under study, except for carcinoma in situ of the cervix, superficial non-invasive bladder cancer, or adequately treated stage I non-melanoma skin cancer.\n3. Prior treatment with KRAS G12C inhibitors, KRAS G12D inhibitors, pan-KRAS inhibitors, or other agents of the same class.\n4. Primary central nervous system (CNS) tumors.\n5. Women who are pregnant or breast-feeding.\n6. Participants who have progressive disease or recurrence during neoadjuvant or adjuvant treatment, or within 6 months after the last dose of medication.","ALL","18 Years",{"count":196,"type":197},80,"ESTIMATED","INTERVENTIONAL",[200,201],"PHASE1","PHASE2","The purpose of this study is to determine the safety and efficacy of pan KRAS inhibitor JAB-23E73 in combination with nab-paclitaxel and gemcitabine in participants with metastatic PDAC harboring KRAS gene alterations.",[204],"Metastatic Pancreatic Ductal Adenocarcinoma",[206,207,208,209,210,211,212,213],"KRAS","KRAS mutation","KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12S, KRAS G12A,","Pan-KRAS","Pancreatic ductal adenocarcinoma","KRAS-mutant tumor","Targeted Therapy","JAB-23E73","NOT_YET_RECRUITING","2026-06-08",{"date":217,"type":218},"2026-06-10","ACTUAL",{"date":220,"type":197},"2026-06-22",{"date":222,"type":197},"2030-12-31",{"name":5,"class":6},13]